The Centers for Medicare & Medicaid Services (CMS) has proposed significant updates to its national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR), potentially expanding access for Medicare beneficiaries with severe aortic stenosis (AS).

The proposal would extend Medicare coverage to include select patients with asymptomatic severe aortic stenosis through coverage with evidence development (CED). This reflects growing clinical evidence that earlier intervention may improve outcomes compared with traditional watchful waiting. The change follows expanded FDA indications for certain TAVR devices, including Edwards Lifesciences’s Sapien valve platform, supported by clinical trial data showing benefits from treating some patients before symptoms develop.

CMS is also proposing to remove the CED requirement for symptomatic patients, meaning Medicare coverage would no longer require enrollment in clinical studies or registries. This could reduce administrative barriers, simplify patient access, and allow hospitals to treat eligible patients more efficiently.

A key element of the proposal is the potential expansion of the TAVR market. Asymptomatic severe AS represents a larger patient population than the currently treated symptomatic population, creating the possibility of earlier diagnosis, more referrals, and increased procedural volumes. This could accelerate growth for companies that provide TAVR technologies.

Edwards Lifesciences could be particularly positioned to benefit because TAVR is a major component of its business and the company has invested heavily in clinical evidence supporting earlier intervention. The FDA expansion of its Sapien platform into asymptomatic severe AS, along with clinical data supporting early treatment, strengthens Edwards’ position as hospitals evaluate new TAVR pathways. Earlier treatment could increase demand for valve systems, procedural support, and related structural heart services.

The proposal may also influence competitive dynamics among major TAVR manufacturers, including Medtronic and Boston Scientific. Companies with strong physician adoption, clinical evidence, and established structural heart programs may be better positioned to capture incremental growth as the eligible patient population expands.

CMS is also considering changes to hospital and operator volume requirements, potentially allowing more hospitals to establish or expand TAVR programs. While this could improve patient access, CMS has maintained the requirement for multidisciplinary heart team participation, preserving the collaborative model between interventional cardiology and cardiac surgery.

If finalized, the policy could reshape severe AS treatment by moving TAVR earlier in the disease process. For healthcare systems, the change may drive investment in valve clinics, diagnostic imaging, referral networks, and data infrastructure. For device manufacturers, especially Edwards Lifesciences, the expansion could create a meaningful new growth opportunity by increasing the number of patients eligible for TAVR.